title: NICE approval of dimethyl fumarate could benefit thousands living with relapsing-remitting multiple sclerosis.
authors.forename: Daphne
authors.initials: D
authors.lastname: Boulicault
authors.forename: Martin
authors.initials: M
authors.lastname: Duddy
mesh_terms: D002170:Canada; D002986:Clinical Trials as Topic; D000069462:Dimethyl Fumarate / Q000627:therapeutic use*; D017277:Drug Approval; D005544:Forecasting; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007494:Ireland; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D009462:Neurology; D010820:Physicians; D006113:United Kingdom
chemical_list: D007166:Immunosuppressive Agents; D000069462:Dimethyl Fumarate
keywords: alemtuzumab; dimethyl fumarate; glatarimer acetate; multiple sclerosis; natalizumab; therapy; β-interferon